CTLA4 and cancer: On the other hand, immune checkpoint immunotherapy (ICI) in cancer is based on targeting molecules that are abundantly expressed by Treg cells, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and program cell death protein 1 (PD-1), suggesting that therapeutic efficacy may depend on this powerful suppressive cell subset.